Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CNS Pharmaceuticals, Inc. (CNSP)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 0.0 | 0.0 | 15.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 15.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | 100.0% | | | | | |
| Selling, general and administrative [+] | 1.2 | 1.4 | 2.2 | 1.2 | 1.3 | 1.3 | 0.9 | 1.2 |
| General and administrative | 1.2 | 1.4 | 2.2 | 1.2 | 1.3 | 1.3 | 0.9 | 1.2 |
| Research and development | 2.8 | 3.6 | 3.3 | 2.2 | 2.2 | 1.9 | 2.4 | 2.6 |
| Other operating expenses | | | 15.3 | | | | | |
| EBITDA [+] | -4.0 | -4.9 | -5.4 | -3.4 | -3.6 | -3.1 | -3.2 | -3.8 |
| EBITDA growth | 13.0% | 56.6% | 66.2% | -10.3% | -6.5% | -12.8% | 8.3% | 89.8% |
| EBITDA margin | | | -35.1% | | | | | |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -4.0 | -4.9 | -5.4 | -3.4 | -3.6 | -3.1 | -3.3 | -3.8 |
| EBIT growth | 12.9% | 56.4% | 66.1% | -10.3% | -6.5% | -12.8% | 8.3% | 89.6% |
| EBIT margin | | | -35.2% | | | | | |
| Non-recurring items | | | 0.1 | | | | | |
| Interest expense, net [+] | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest income | 0.0 | | | | | | | |
| Pre-tax income | -4.0 | -4.9 | -5.5 | -3.4 | -3.6 | -3.2 | -3.3 | -3.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -4.0 | -4.9 | -5.5 | -3.4 | -3.6 | -3.2 | -3.3 | -3.8 |
| Net margin | | | -35.8% | | | | | |
| |
| Basic EPS [+] | ($1.04) | ($2.59) | ($4.04) | ($0.09) | ($2.67) | ($2.44) | ($3.70) | ($0.14) |
| Growth | -61.2% | 6.2% | 9.1% | -38.5% | 1682.1% | 1563.1% | 1948.5% | 13.9% |
| Diluted EPS [+] | ($1.04) | ($2.59) | ($4.04) | ($0.09) | ($2.67) | ($2.44) | ($3.70) | ($0.14) |
| Growth | -61.2% | 6.2% | 9.1% | -38.5% | 1682.1% | 1563.1% | 1948.5% | 13.9% |
| |
| Shares outstanding (basic) [+] | 3.9 | 1.9 | 1.4 | 40.0 | 1.3 | 1.3 | 0.9 | 27.4 |
| Growth | 190.6% | 47.4% | 55.0% | 45.9% | -94.8% | -94.8% | -94.7% | 66.5% |
| Shares outstanding (diluted) [+] | 3.9 | 1.9 | 1.4 | 40.0 | 1.3 | 1.3 | 0.9 | 27.4 |
| Growth | 190.6% | 47.4% | 55.0% | 45.9% | -94.8% | -94.8% | -94.7% | 66.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|